Industrial Alliance Securities Adjusts Price Target for MediWound (NASDAQ: MDWD) Amid Q1 Challenges

• Industrial Alliance Securities has lowered its price target for MediWound (NASDAQ: MDWD), yet still projects a significant 51.1% upside potential for the biopharmaceutical stock.
• The biopharmaceutical company reported a wider Q1 loss of $0.23 per share and lower revenue of $1.48 million, missing consensus estimates for revenue.
• Despite these challenges, MediWound management reaffirmed its full-year 2026 revenue guidance, though the timeline for its EscharEx Phase III study has been extended.

Industrial Alliance Securities has adjusted its price target for MediWound (NASDAQ: MDWD) to $22.00 from $25.00. MediWound is a biopharmaceutical company that develops, makes, and sells products for tissue repair and regeneration. Despite the reduction, the new target suggests a potential 51.1% upside from its recent stock price of $14.56, offering an updated investment outlook for the company.

This price target change follows MediWound's recent first-quarter report, which revealed a wider loss and lower revenue. The company posted a quarterly loss of $0.23 per share. This is a greater loss than the $0.07 per share reported in the same period last year, though it was better than analyst estimates for earnings per share.

Revenue for the quarter was $1.48 million, a significant decrease from the $3.95 million generated a year ago. As highlighted by Zacks, this figure also missed consensus estimates. Historically, MediWound has surpassed earnings per share estimates three times in the last four quarters but has only exceeded revenue estimates once.

Despite the weak quarter, management reaffirmed its full-year 2026 revenue guidance, projecting between $24 million and $26 million. CEO Ofer Gonen stated the company continues to execute its strategic priorities. These include advancing its main programs, EscharEx for chronic wounds and the global expansion of NexoBrid for severe burns, highlighting ongoing clinical trials and product development efforts.

However, the company faces operational challenges. The timeline for its EscharEx Phase III study has shifted by one quarter due to slower-than-expected enrollment. MediWound now expects to complete enrollment and have an interim assessment by the end of the first quarter of 2027, impacting its development timeline and future biotech stock performance.